NCT03517176View on ClinicalTrials.gov

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

June 19, 2020

Study Completion Date

June 19, 2020

Conditions
Pancreatic CancerPancreatic Ductal Adenocarcinoma
Interventions
DRUG

CEND-1

CEND-1 will be provided as concentrate for solution to be administered via IV injection.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be provided as solution to be administered via IV infusion.

DRUG

Gemcitabine

Gemcitabine will be provided as solution to be administered via IV infusion.

Trial Locations (3)

3004

Alfred Hospital, Melbourne

5011

Queen Elizabeth Hospital, Woodville South

6008

St John of God Hospital, Subiaco

Sponsors
All Listed Sponsors
lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT03517176 - CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter